drugset / Trial / NCT04624672

Treatment of GLP-1 for Diabetic Bariatric Patients

NCT04624672

Phase 4 Terminated 3 enrolled Geisinger Clinic Novo Nordisk A/S · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

This study is for patients that are diabetic, and require insulin for glycemic control, and going through the bariatric surgery process. This is a prospective study that is trying to determine if the introduction of a semaglutide increases the remission rates of diabetes post-operatively.

Timeline

Start
2021-08-25
Primary completion
2022-07-18
Completion
2022-08-17

Drugs

EvaluationDrugModalityDoseRoute
Comparator Semaglutide Peptide 1 mg Other